2022
DOI: 10.1016/j.tranon.2022.101445
|View full text |Cite
|
Sign up to set email alerts
|

Assessment of salivary gland function after 177Lu-PSMA radioligand therapy: Current concepts in imaging and management

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
7
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 11 publications
(7 citation statements)
references
References 62 publications
0
7
0
Order By: Relevance
“…Indeed, the first review from Lunger et al [ 32 ] reports that [ 225 Ac]Ac-PSMA-617 could be a promising alternative for patients developing progression under [ 177 Lu]Lu-PSMA-617 but would induce mostly permanent xerostomia. Another more recent review [ 17 ] shows a low morbidity profile of [ 225 Ac]Ac-PSMA-617 and a loss of efficacy in patients pre-treated with [ 177 Lu]Lu-PSMA-617. Further randomized controlled trials are required to clarify these data and position [ 225 Ac]Ac-PSMA-617 in relation to [ 177 Lu]Lu-PSMA-617.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Indeed, the first review from Lunger et al [ 32 ] reports that [ 225 Ac]Ac-PSMA-617 could be a promising alternative for patients developing progression under [ 177 Lu]Lu-PSMA-617 but would induce mostly permanent xerostomia. Another more recent review [ 17 ] shows a low morbidity profile of [ 225 Ac]Ac-PSMA-617 and a loss of efficacy in patients pre-treated with [ 177 Lu]Lu-PSMA-617. Further randomized controlled trials are required to clarify these data and position [ 225 Ac]Ac-PSMA-617 in relation to [ 177 Lu]Lu-PSMA-617.…”
Section: Discussionmentioning
confidence: 99%
“…Xerostomia is one of the common adverse effect reported with [ 177 Lu]Lu-PSMA-617. Fortunately, some studies about [ 177 Lu]Lu-PSMA-617 in prostate cancer showed that xerostomia more often remains at grade 1 or 2 [ 17 , 18 ]. In addition, in a VISION study, a [ 68 Ga]Ga-PSMA-11 PET-CT is required to decide on the eligibility for treatment with [ 177 Lu]Lu-PSMA-617 [ 19 ].…”
Section: Use Of [ 177 Lu]lu-psma-617 In Francementioning
confidence: 99%
“… “Unacceptable” xerostomia may eventually be improved by retrograde sialendoscopy and flushing with steroids (weak recommendation based on a single cohort study [ 102 ]). Due to its own side effects and contra-indications, the use of parasympathomimetics (e.g., the FDA and EMA approved pilocarpine) must consider patient’s individual situation because benefits and risks could be closely balanced [ 103 ]. A flare-up of tumor-related pain can occur during the first week following therapy but in responding patients often improves below baseline after the second week.…”
Section: Performing the 177 Lu-psma-rlt Proceduresmentioning
confidence: 99%
“… The clinical relevance and potential consequences of the tumor-sink-effect, i.e., (in)variance of normal organ dosimetry at very high tumor load [ 129 , 130 ], are still unclear and need to be studied. Several drug interventions (e.g., oral glutamate, atropine injections, pre-dosing with unlabeled PSMA ligands) to reduce off-target uptake of PSMA ligands in salivary glands or kidneys have been suggested [ 103 ]. Due to the limited evidence available, at this point, no general recommendation can be given.…”
Section: Open Points/miscellaneousmentioning
confidence: 99%
See 1 more Smart Citation